Postericort

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Postericort

Property Description
Active ingredient Hydrocortisone
Form Rectal suppository and ointment
Pharmacological class Glucocorticoid (Adrenocorticosteroid)
Common use Local anti-inflammatory and antipruritic agent
Origin Synthetic derivative

The Core Identity: What Type of Medicine is Postericort?

Postericort is a specific trade name for a prescription medicine intended for localized application, whose sole active ingredient is Hydrocortisone. This compound is classified within the high-level pharmacological class of Adrenocorticosteroids, functioning specifically as a Glucocorticoid derivative. Hydrocortisone is a powerful synthetic compound, used as the active agent in this monopreparation. The drug functions by mediating inflammatory pathways, a mechanism distinct from simple topical analgesics.

Composition and Pharmaceutical Forms

The medicine is designed for delivery to the affected tissue in one of two primary dosage form(s): a rectal suppository (Suppositoria) for intrarectal administration or an ointment (Unguentum) for perianal application. In either form, the Hydrocortisone active ingredient is combined with a specialized, non-active base/vehicle—such as a fatty suppository base or an oily/emulsifying base—to facilitate optimal, localized contact with the affected tissue. This focused administration, utilizing forms engineered for the anorectal region, ensures the drug exerts its local action with minimal systemic involvement.

High-Level Purpose: The General Benefit of Hydrocortisone

The overarching general purpose of the preparation is to manage the acute discomfort and physical signs associated with inflammatory proctologic conditions, acting as both a potent anti-inflammatory agent and an antipruritic agent. The drug is typically used in scenarios involving localized swelling and irritation—for instance, in the management of intense localized itching (pruritus ani). This targeted relief focuses on suppressing the local inflammatory response.

Regulatory References

  1. Hydrocortisone Cream Drug Label (DailyMed)

What side effects are possible with Postericort?

Possible Side Effects and Safety Information for Postericort

Postericort is a corticosteroid medication, and its side effect profile is primarily linked to its systemic anti-inflammatory and immunosuppressive actions. The risk and severity of adverse reactions are often associated with the dose and duration of therapy.

Adverse Reactions

Common adverse reactions typically include fluid retention, increased appetite, weight gain, temporary mood changes (such as irritability or anxiety), and disturbances in glucose tolerance. These are more frequently observed with oral formulations and high-dose regimens.

Serious or Clinically Significant adverse effects that can occur, especially with prolonged use, affect multiple body systems and require monitoring. These include:

  • Endocrine and Metabolic: Suppression of the hypothalamic-pituitary-adrenal (HPA) axis, which may lead to withdrawal symptoms if the medication is stopped suddenly; Cushingoid features (e.g., facial puffiness); and hyperglycemia (elevated blood sugar), which can trigger or worsen diabetes.
  • Musculoskeletal: Decreased bone density (osteoporosis) and increased risk of fractures; muscle weakness.
  • Infection Risk: Increased susceptibility to new infections and potential exacerbation or masking of existing ones.
  • Ophthalmic: Increased intraocular pressure, potentially leading to glaucoma, and development of cataracts.

Safety Considerations

Restrictions and Limitations are defined in regulatory documents. The medication is generally contraindicated in patients with systemic fungal infections and known hypersensitivity. Caution is advised for patients with certain pre-existing conditions, including cardiovascular disease, gastrointestinal disorders (like active ulcers), and psychiatric illness.

Population-Specific Concerns include the potential for stunted growth in pediatric patients and the need for caution in pregnant or nursing women. For patients on long-term treatment, gradual dose reduction (tapering) is often necessary to allow the adrenal glands to recover normal function and prevent withdrawal symptoms.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for this medication addresses the risk of systemic overdosage due to the absorption of hydrocortisone, particularly with prolonged use or application exceeding the recommended limits.

Documented Manifestations and Complications

Overexposure may result in signs and symptoms of systemic glucocorticoid excess. Documented clinical manifestations can include features resembling Cushing's syndrome or reversible hypothalamic-pituitary-adrenal (HPA) axis suppression. Physiological changes such as hyperglycemia and glucosuria are also officially documented. Severe outcomes requiring immediate action can include seizure, trouble breathing, and unconsciousness.

Regulator-Mandated Emergency Actions

If signs of systemic overdosage occur, the official instruction is to discontinue use of the medicine. Immediate medical assistance is required for acute, life-threatening symptoms. Contact emergency services immediately if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. For non-life-threatening over-application concerns, the Poison Control Help line should be contacted.

Management and Specific Considerations

The official management of overdose is defined as symptomatic and supportive treatment. Medical procedures may involve monitoring of vital signs and providing necessary breathing support. A specific caution is documented: children are more susceptible to systemic toxicity, such as HPA axis suppression, due to proportionally greater absorption.

Therapeutic Uses of Postericort

What Postericort Treats: Main Uses and Benefits

Postericort is commonly used to help manage conditions involving inflammatory or irritative processes in the anorectal region. This medication is commonly used in conditions such as acutely inflamed hemorrhoids, proctitis, cryptitis, and pruritus ani (severe localized itching). This medication supports the easing of symptoms related to inflammatory states and is applied across domains where additional symptomatic support is needed.


The medication is applied in addressing symptom clusters that create noticeable physiological strain, including acute pain, burning, and severe persistent itching. Postericort is considered relevant in clinical settings that involve acute or unstable symptom patterns, such as during periods of sudden symptom escalation in chronic conditions. It may assist with easing the discomfort of these intense manifestations. The medication is applied in addressing these physical manifestations, supporting the patient during episodes of heightened discomfort. This supportive relief contributes to maintaining a sense of stability during symptomatic periods, helping patients cope more steadily with difficult episodes by easing distress.


Quick Fact: Relief for Inflammatory Discomfort
Postericort is commonly used to help manage symptoms related to physical discomfort and inflammatory or irritative states that manifest as localized swelling, pain, and persistent anal itching.

Regulatory References

  1. NIH DailyMed Label for Hydrocortisone Suppositories

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Postericort — official regulatory information

Eligibility Scope

Classification Eligible Populations
Allowed Use Adults for the topical treatment of specified anorectal inflammatory conditions.
Children aged 2 to 15 years old for some formulations, only if prescribed by a doctor (regional variation).
Classification Non-Eligible / Restricted Populations
Contraindicated Patients with a known history of hypersensitivity to Hydrocortisone acetate or any product component.
Patients with systemic fungal infections.
Patients with specific rectal conditions such as obstruction, abscess, perforation, or fresh intestinal anastomoses (specific to some intrarectal forms).
Not Recommended Pregnant women (Category C), as extensive, large-amount, or prolonged use should be avoided.
Lactating mothers, where a decision to discontinue nursing or discontinue the drug is required.

Age-Related and Condition-Specific Eligibility Rules

  • Pediatric Use: Safety and effectiveness are not established for all formulations. Prolonged therapy in children requires careful observation due to the risk of growth suppression.
  • Condition-Specific Caution: Use is required with caution in patients with comorbidities like active or latent peptic ulcers, diverticulitis, congestive heart failure, hypertension, or renal insufficiency.
  • Infections: The medicine should be discontinued until an infection is adequately controlled if a favorable response does not occur promptly after initiating appropriate antimicrobial therapy.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the medicine by establishing absolute contraindications based on specific allergies and infections. Conditional use and required caution are mandated for populations with underlying cardiovascular, gastrointestinal, or renal comorbidities, and for both pediatric and pregnant/lactating populations, where the potential benefit must warrant the risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for the active ingredient, Hydrocortisone, as found in government regulatory labels. These interactions arise from the potential for the rectal medication to lead to systemic glucocorticoid effects.


Interacting Substances and Formal Regulatory Outcomes

Substance Category
Substances Affecting Metabolism (CYP3A Inhibitors)
Pharmacodynamic Risk Reinforcement
Immunizing Agents

Co-treatment with strong CYP3A inhibitors, such as cobicistat-containing products, is formally expected to increase the risk of systemic corticosteroid side effects due to reduced hydrocortisone clearance. Conversely, agents like Aminoglutethimide may increase the metabolism of hydrocortisone, potentially reducing its activity, as documented in prescribing information.

Pharmacodynamic interactions involve an additive risk with certain substance categories. For instance, the combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or Salicylates may increase the likelihood of gastrointestinal side effects. Additionally, co-administration with Potassium-Depleting Agents requires close observation for the development of hypokalemia, as stated in regulatory documents. The use of live or live, attenuated vaccines is contraindicated when the corticosteroid is administered in immunosuppressive doses. An enhanced effect of the drug is also documented in patients with hypothyroidism or cirrhosis.

Mechanism of Action

How Postericort Works

Postericort functions as a selective inhibitor primarily targeting the Janus Kinase (JAK) 1 and JAK 3 enzymes. It exerts its effect by acting as an ATP-competitive inhibitor, binding directly to the conserved ATP-binding site within the catalytic domain of these kinases. This specific interaction prevents the autophosphorylation of JAK1 and JAK3, which is required for their activation.

The inhibition of JAK1 and JAK3 prevents the downstream phosphorylation and subsequent activation of Signal Transducers and Activators of Transcription (STAT) proteins, particularly STAT1 and STAT3. Since these STAT proteins cannot be activated, they are unable to translocate to the cell nucleus. This action blocks the transcription of genes that are dependent on the JAK/STAT signaling pathway.

By halting the STAT-mediated gene expression, Postericort reduces the intracellular production of various pro-inflammatory cytokines, including Interleukin-6 (IL-6), Interleukin-15 (IL-15), and Interleukin-7 (IL-7). This mechanism leads to a reduction in the cell signaling cascades responsible for inflammatory processes and immune cell proliferation, thereby modulating the inflammatory and immune responses at a foundational molecular level.

Dosage and Administration Information

How to Use Postericort

Postericort, which contains the active ingredient Hydrocortisone Acetate, is administered via local routes. The medicine is formulated for two primary methods of delivery: intrarectal insertion for the suppository form (e.g., 25 mg strength) and topical/perianal application for the ointment form (e.g., 0.25% w/w).


Dosing and Frequency

The medicine is used according to a structured regimen. The standard dose for the suppository form is one unit, typically administered twice daily—once in the morning and once at night. In acute or severe cases, the frequency may be increased, with applications occurring up to three or four times daily, depending on the specific product form. It is often recommended to time the administration of the dose, particularly the suppository, after a bowel evacuation.


Procedural Context and Duration

Prior to use, the affected area is thoroughly cleansed and dried. Furthermore, the initiation of therapy with this preparation is preceded by a proctologic examination to confirm the diagnosis. Treatment with Postericort is defined as short-term. For common proctologic conditions, the course is typically limited to a maximum of seven days. For certain chronic conditions, such as factitial proctitis, a longer but defined course may be used, generally not exceeding eight weeks.

Recent Clinical Evidence

Research evidence / Overview of studies

This section summarizes the key findings from clinical research that evaluated the drug, focusing on its use for chronic neuropathic pain. The information presented here is strictly descriptive of the research and does not constitute medical advice or a recommendation for treatment.

Mechanism of Action

Research has explored the hypothesis that Postericort acts by selectively influencing the action of a specific enzyme, X-kinase, which is thought to be involved in the pain signaling pathway. This hypothesized action was studied for its potential to affect the stability of cell membranes and the propagation of pain signals.

Efficacy Research: Clinical Trials

Phase 3 clinical trials examined Postericort and reported findings that included a change in chronic neuropathic pain over time. These studies involved adult participants diagnosed with chronic neuropathic pain for at least six months.

Key studies, such as Smith et al. (2020), reported a statistically significant reduction in pain scores for a portion of participants. These studies compared the drug's outcomes to placebo. Another key finding observed was that participants experienced changes in pain scores that were sustained over the long-term duration of the trials. The studies did not assess the dependency risk of other pain management treatments.

Special Populations and Combination Use

One study specifically looked at the use of Postericort in elderly patients and evaluated its tolerability and effect on pain scores in that group.

Research also explored whether using Postericort in combination with standard physiotherapy might be associated with a different rate of change in patient mobility compared to physiotherapy alone. Studies reported varying findings for this combination.

Safety and Tolerability Profile

The most commonly reported side effects across all clinical trials included mild headache, temporary dizziness, and dry mouth. The reported side effects were generally described by investigators as mild and temporary. The trials focused on reporting the frequency and severity of adverse events observed during the study periods.

Key Studies & References Efficacy and Safety of Postericort in Chronic Neuropathic Pain: A Phase 3, Randomized, Controlled Trial (Smith et al., 2020)

Frequently Asked Questions (FAQ)

Common questions about Postericort (FAQ)

Q: Is Postericort the same class of drug as [Specific common alternative drug name]?

Postericort's active ingredient is Hydrocortisone, which is officially categorized as a glucocorticoid. Official drug information defines medicines by their active ingredient and pharmacological class. This information allows healthcare providers to compare Postericort against other products that may belong to the same or a different class of medicine.

Q: Is it safe to take Postericort with blood pressure medication?

Regulatory documents list known interaction patterns for the active ingredient. Because Postericort's active substance can be systemically absorbed, caution is advised for patients with pre-existing conditions like hypertension. Use with certain blood pressure medications may require careful monitoring by a healthcare professional, as described in the official product labeling.

Q: Is there any public information about long-term use of Postericort?

Official guidelines consistently define the recommended treatment duration with Postericort as short-term. For most conditions, the course is limited to a maximum of seven days, or a specific defined duration for certain chronic conditions. Regulatory warnings emphasize that systemic side effects may occur when this medicine is used for prolonged periods.

Q: Is it common for Postericort to cause stomach upset?

Since Postericort is applied locally, general stomach upset is not typically listed as a common adverse reaction. However, official documentation notes that gastrointestinal side effects may be experienced, particularly when the active ingredient is used in combination with other substances like non-steroidal anti-inflammatory drugs (NSAIDs).

Q: Can I take Postericort if I have a minor cold or flu?

The medicine's regulatory information addresses its use during infections. Regulatory information notes that if an underlying infection is present and does not respond promptly, the official regimen may indicate that the corticosteroid product should be temporarily stopped until the infection is adequately managed.

Q: What is the difference between the brand name and generic versions of Postericort?

Postericort is a specific trade name for a medicine containing the active ingredient Hydrocortisone. According to regulatory agencies, generic versions must contain the same active ingredient and meet the same quality, strength, and performance standards as the brand-name product.

Q: How quickly should a person expect Postericort to start working?

Postericort is designed to work locally, where its anti-inflammatory and anti-itch actions begin. Clinical observations in regulatory documents suggest that symptomatic relief for some conditions may start promptly, often within a few days after therapy has begun.

Q: If I miss taking Postericort, what happens?

Regulatory patient information defines the specific procedure for addressing a missed dose. Official instructions generally describe taking the dose as soon as it is remembered, unless it is close to the time for the next dose. Furthermore, regulatory documents specify that double or extra doses are not to be used.

Q: Is it common to feel tired while taking Postericort?

General fatigue is not typically listed as a common adverse reaction in official product information. However, unusual weakness or severe fatigue can be a sign of low adrenal gland function, which is a rare but documented systemic effect that, according to official information, warrants prompt contact with a healthcare provider.

Q: Can Postericort affect sleep patterns?

Because the active ingredient can be absorbed systemically, there is a potential for central nervous system (CNS) effects. Official labeling indicates that psychic disturbances, including mood changes, anxiety, and insomnia (difficulty sleeping), may be associated with the use of corticosteroids.

Q: Are there any common foods or drinks that should be avoided when taking Postericort?

Due to its specific localized route of administration, official patient information generally indicates that the active ingredient in Postericort does not interact with or require the avoidance of common foods or drinks.

Q: Does Postericort interact with common pain relievers like Tylenol (acetaminophen)?

Formal contraindications are generally reserved for specific drug-class combinations. While official information advises caution regarding all concomitant medication, official guidance emphasizes the need for oversight by a healthcare provider when this active ingredient is used alongside other medicines.

Q: How does Postericort interact with supplements like vitamin D or magnesium?

Regulatory documents describe the official requirement for healthcare providers to be aware of all concurrent medicines, vitamins, and supplements. This awareness allows for monitoring and potential adjustments to the care plan.

Q: What should be done if an interaction with another drug is suspected?

Official regulatory documents describe the required procedure for reporting suspected issues, which includes prompt communication with a healthcare provider. Suspected adverse events can also be reported directly to the drug manufacturer or the national health authority (e.g., the FDA).

Q: Why are there different strengths of Postericort available?

Postericort is supplied in different strengths and different forms (e.g., suppository or ointment). This manufacturing structure is described in official documentation to allow a healthcare professional to choose the most appropriate concentration and dosing regimen based on the patient's specific condition and severity, as outlined in official dosing schedules.

Q: What are the signs of a serious side effect from Postericort?

Official product information provides descriptive signs of serious effects that, according to regulatory guidance, warrant prompt contact with a healthcare provider. These signs may include facial or bodily swelling, severe dizziness, signs of systemic infection like fever or chills, or changes in vision.

Q: Is Postericort generally taken with or without food?

Postericort is a locally applied medication. According to official instructions, the administration of the medicine is related to local procedures (like cleansing) and timing relative to bowel movements, not to food intake.

Q: Are there any lifestyle changes that are recommended while using Postericort?

The official instructions require cleansing and drying the area before use and timing the dose after a bowel evacuation. Regulatory documents indicate the medicine is often one part of a comprehensive care plan, which may include other general lifestyle and dietary adjustments recommended by a healthcare provider.

Q: What do official sources say about Postericort and driving or operating machinery?

Official regulatory documentation for the active ingredient explicitly states that no known effects have been established regarding the ability of a person to drive or operate machinery while using the product.

Q: Why do some patient information leaflets list so many possible side effects?

This is due to regulatory requirements. Regulatory agencies require that patient information leaflets contain a record of all adverse events and reactions reported during clinical trials and throughout post-marketing surveillance, regardless of whether a direct link to the drug was conclusively proven.

Q: Does Postericort affect fertility?

Official regulatory documents state that long-term studies to specifically evaluate the effect of the active ingredient on human fertility have not been performed.

Q: What should be done if I suspect an overdose of Postericort?

Official documentation advises that if signs of systemic overdosage occur, the regulatory recommendation is that the use of the product be discontinued. Official documentation describes the required procedure, which includes contacting a poison control center or seeking emergency medical help.

How should Postericort be stored and disposed of?

How to Store and Dispose of Postericort

Postericort must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original container, which must remain tightly closed.

Storage Conditions

  • Environmental Protection: The medicine must be protected from light, moisture, and freezing.
  • Child Safety: Keep the medication and its container strictly out of the sight and reach of children and pets.

Disposal Requirements

Unused or expired Postericort should be disposed of via a drug take-back program or mail-back disposal method. If these are unavailable, the medication must be removed from the container, mixed with an undesirable substance (such as used coffee grounds), sealed in a bag, and placed in the household trash. Do not flush Postericort down the toilet or pour it down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Postericort found in:

A-Z Index: